Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer is a phase 2/3 interventional study registered as NCT07392892, led by Pfizer, and recruiting on the registry. Official title: A phase 2/3 interventional study of PF-08634404 in combination with chemotherapy in treatment-naïve participants with locally advanced or metastatic gastric, gastroesophageal junction, or oesophageal adenocarcinoma. Planned enrolment is 840 participants (estimated). The study started in 2026-05-14 and primary completion is expected in 2031-07-22. No results have been posted on ClinicalTrials.gov.